Atara Biotherapeutics Gets FDA Clearance for ATA3219 IND Application
By Chris Wack
Atara Biotherapeutics said the U.S. Food and Drug Administration has cleared an investigational new drug application for ATA3219, an allogeneic, anti-CD19 chimeric antigen receptor T-cell monotherapy for the treatment of systemic lupus erythematosus.
The Phase 1 study will evaluate the safety and preliminary efficacy of ATA3219 in subjects with lupus nephritis.
Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 CAR+ T cells. ATA3219 is designed to be given as a one-time infusion and followed for safety and efficacy.
Each dose level is designed to enroll 3-6 patients, with the first subject expected to be enrolled in the second half of 2024.
The ATA3219 IND submission included in vitro data reflecting the CD19 antigen-specific functional activity of ATA3219 and chimeric antigen receptor-mediated activity against B cells from SLE patients. ATA3219 led to robust CD19-specific B-cell depletion compared to controls.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 29, 2024 09:35 ET (14:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits